Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Long-Term Investments (2019 - 2024)

Historic Long-Term Investments for Nurix Therapeutics (NRIX) over the last 6 years, with Q3 2024 value amounting to $9.5 million.

  • Nurix Therapeutics' Long-Term Investments fell 414.9% to $9.5 million in Q3 2024 from the same period last year, while for Aug 2024 it was $9.5 million, marking a year-over-year decrease of 414.9%. This contributed to the annual value of $7.4 million for FY2023, which is 8838.27% down from last year.
  • According to the latest figures from Q3 2024, Nurix Therapeutics' Long-Term Investments is $9.5 million, which was down 414.9% from $9.4 million recorded in Q2 2024.
  • In the past 5 years, Nurix Therapeutics' Long-Term Investments ranged from a high of $137.2 million in Q4 2021 and a low of $7.4 million during Q4 2023
  • For the 5-year period, Nurix Therapeutics' Long-Term Investments averaged around $59.3 million, with its median value being $51.5 million (2022).
  • In the last 5 years, Nurix Therapeutics' Long-Term Investments soared by 1786245.06% in 2020 and then tumbled by 8838.27% in 2023.
  • Nurix Therapeutics' Long-Term Investments (Quarter) stood at $90.9 million in 2020, then surged by 50.94% to $137.2 million in 2021, then plummeted by 53.44% to $63.9 million in 2022, then plummeted by 88.38% to $7.4 million in 2023, then increased by 27.64% to $9.5 million in 2024.
  • Its Long-Term Investments stands at $9.5 million for Q3 2024, versus $9.4 million for Q2 2024 and $10.3 million for Q1 2024.